Risk Indicators in Patients With Ventricular Fibrillation During Acute Myocardial Infarction

This study is currently recruiting participants.

Verified by University of Heidelberg, May 2005

First Received: September 10, 2005 No Changes Posted

Sponsored by:	University of Heidelberg
Information provided by:	University of Heidelberg
ClinicalTrials.gov Identifier:	NCT00175942

Purpose

Sudden cardiac death is in most cases triggered by ischemia-related ventricular tachyarrhythmias and accounts for 50% of deaths from cardiovascular disease in developed countries. Chronic elevation of indicators of coagulation activation has been found in patients with coronary heart disease , but a role of coagulation activation and proinflammatory state as a potential risk factor for ventricular fibrillation (VF) during acute myocardial infarction has not been investigated.

Condition
Acute Myocardial Infarction Sudden Cardiac Death

Study Type:	Observational
Study Design:	Longitudinal, Defined Population, Retrospective/Prospective Study
Official Title:	Indicators of Coagulation Activation and Inflammation Contributing to Ventricular Fibrillation Complicating Acute Myocardial Infarction

Resource links provided by NLM:

Genetics Home Reference related topics: Brugada syndrome short QT syndrome

MedlinePlus related topics: Cardiac Arrest Heart Attack

U.S. FDA Resources

Further study details as provided by University of Heidelberg:

Estimated Enrollment:	300
Study Start Date:	February 2003

Detailed Description:

Sudden cardiac death (SCD) is in most cases triggered by ischemia-related ventricular arrhythmias and is responsible for 50% of the mortality from cardiovascular disease in developed countries (1). Chronic elevation of indicators of coagulation activation and inflammation has been found in patients with coronary heart disease and may contribute to vasculatory disorders probably contributing to the development of arrhythmogenesis. However, the role of coagulation activation as a potential risk factor for ventricular fibrillation during acute myocardial infarction has not been investigated yet.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

ST-elevation myocardial infarction ventricular fibrillation during acute MI

Exclusion Criteria:

NSTEMI coagulation disorders, e.g.intake of coumadin

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00175942

Contacts

Contact: Elif Elmas, MD, Dr.	00496213833988
Contact: Martina Brückmann, MD, Dr.

Locations

Germany
University Hospital of Mannheim, University of Heidelberg	Recruiting
Mannheim, Germany, 68167
Sub-Investigator: Elif Elmas, MD. Dr

Sponsors and Collaborators

University of Heidelberg

Investigators

Principal Investigator:

Carl E. Dempfle, Prof.Dr.

University Hospital of Mannheim, University of Heidelberg

More Information

No publications provided

Study ID Numbers:	0229.3
Study First Received:	September 10, 2005
Last Updated:	September 10, 2005
ClinicalTrials.gov Identifier:	NCT00175942 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Heidelberg:

acute myocardial infarction
ventricular fibrillation
coagulation
inflammation

Study placed in the following topic categories:

Death
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Heart Arrest
Ischemia
Inflammation
Paroxysmal Ventricular Fibrillation

Necrosis
Death, Sudden
Death, Sudden, Cardiac
Infarction
Myocardial Infarction
Ventricular Fibrillation
Arrhythmias, Cardiac

Additional relevant MeSH terms:

Death
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Heart Arrest
Ischemia
Necrosis
Pathologic Processes

Death, Sudden
Cardiovascular Diseases
Death, Sudden, Cardiac
Infarction
Myocardial Infarction
Ventricular Fibrillation
Arrhythmias, Cardiac

ClinicalTrials.gov processed this record on September 02, 2009